Mumbai Based Pharmaceutical Giant Cipla  Partners With Govt Labs To Produce Effective Drugs For Covid-19Cipla Head Office. (Alyssa Banta/Newsmakers)

Mumbai based pharmaceutical giant Cipla has embarked on fast-tracked development of drugs to cure COVID-19 in partnership with Government laboratories, while repurposing its gamut of respiratory, asthma, antivirals and HIV drugs to defeat the spread of COVID-19 in India, reports Times of India.

It should also be noted that Cipla's drug Actemra which is used in treating rheumatoid arthritis was recently approved by China for usage in the treatment of patients with severe complications associated with COVID-19.

Known for many innovations in respiratory, HIV and flu therapy, Cipla's promoter Yusuf Hamied said, "We consider it a nationalistic duty to put up all our resources to benefit the country."

The company, which was one of the first ones to launch a generic cure to H1N1 influenza is now aiming to become the first domestic company to introduce drugs against COVID-19.

The company is presently looking into the production of raw materials with the help of Government laboratories for antiviral compounds like favipiravir, remidesivir and bolaxavir. It should be noted though that the final drugs will take about six months to be launched after the procurement of raw materials (active pharmaceutical ingredients) begins.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Advertisement